Predictors and Prognostic Factors on the Acute Ischemic Stroke

NCT03122002 | Terminated

• 1 other identifier: Know more about AIS
• Study Type: observational
• Target: 1,200
• Locations: 1 country
• Sites: 1

Brief Summary

Through 5 years continuous observation of acute ischemic stroke patients in Neurology Department of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, clinical data about emergency treatment (neurological score, examination and treatment), medical data after admission (neurological score, inspection, examination and treatment) and long-term prognosis (neurological score) was collected. The outcomes were set as the score scale, all blood test index and examination index of the research objects at specific period after illness. Through statistical analysis and comparison of different in-hospital clinical data in predicting the outcome of the patients, our study will provide more evidence-based solutions for the treatment and prediction of acute ischemic stroke.

Conditions

Ischemic Stroke

Keywords

Ischemic Stroke; Cerebral Infarction; Cerebrovascular Disorders

Outcome Measures

Primary Outcomes (1)

• Modified Rankin Scale scores

  0 = No symptoms; 1 = No significant disability. Able to carry out all usual activities, despite some symptoms; 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 = Moderate disability. Requires some help, but able to walk unassisted; 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 = Dead.

  Change from Baseline mRS score at 24 months

Secondary Outcomes (10)

• Re-admission to the hospital

  24 months

• Cerebral and Cardio vascular diseases

  24 months

• Neurological deterioration-1

  Change from Baseline NIHSS score at 24 months

• Neurological deterioration-2

  Change from Baseline FAQ score at 24 months

• Cognitive dysfunction

  Change from Baseline MMSE score at 24 months

Study Arms (2)

Patients With Ischemic Stroke

The patients with all types of ischemic stroke including TIA, small vessle diseases, MCAO, and ect. These patients will be recorded their emergency treatment, medical history, details about their drug therapy, results of their routine blood test and image scan, and whether they receive intravascular therapy in time or not.

Drug: Drug Therapy; Diagnostic Test: Routine Blood Test and Image Scan; Other: Intravascular therapy; Other: Emergency Treatment; Other: Medical history

Healthy Control

The patients admitted to hospital for symptoms like dizzness and headache, which later proved to be not related to cerebral vascular diseases, would be treated as control. Their medical history and the results of their routine blood test and image scan will be recorded.

Diagnostic Test: Routine Blood Test and Image Scan; Other: Medical history

Interventions

Drug Therapy DRUG

For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes

Also known as: Aspirin, Clopidogrel, Statin

Patients With Ischemic Stroke

Routine Blood Test and Image Scan DIAGNOSTIC_TEST

Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)

Healthy Control; Patients With Ischemic Stroke

Intravascular therapy OTHER

Intravascular therapy including thrombectomy

Patients With Ischemic Stroke

Emergency Treatment OTHER

Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.

Patients With Ischemic Stroke

Medical history OTHER

Medical history including hypertension, diabetes, hyperlipemia and ect.

Healthy Control; Patients With Ischemic Stroke

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All patients with ischemic stroke admitted to Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology from April 1, 2017 to December 31, 2021 will be included.

You may qualify if:

• ≥18 years old, of either sex
• Confirmation by CT scan
• Willingness to participate in the study and comply with its procedures by signing a written informed consent

You may not qualify if:

• Cerebral hemorrhagic infarction confirmed by CT scan
• Patients with severe systemic disease who are expected to survive for no more than three months
• Unwilling to participate in the study

Sponsors & Collaborators

• Tongji Hospital: lead

Study Sites (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

Location

Related Publications (2)

• Shang K, Chen X, Cheng C, Luo X, Xu S, Wang W, Liu C. Arterial Tortuosity and Its Correlation with White Matter Hyperintensities in Acute Ischemic Stroke. Neural Plast. 2022 Mar 24;2022:4280410. doi: 10.1155/2022/4280410. eCollection 2022.

  PMID: 35369646 DERIVED

• Qin C, Zhao XL, Ma XT, Zhou LQ, Wu LJ, Shang K, Wang W, Tian DS. Proteomic profiling of plasma biomarkers in acute ischemic stroke due to large vessel occlusion. J Transl Med. 2019 Jul 1;17(1):214. doi: 10.1186/s12967-019-1962-8.

  PMID: 31262327 DERIVED

Biospecimen

Retention: SAMPLES WITH DNA

blood sample

MeSH Terms

Conditions

Ischemic Stroke; Cerebral Infarction; Cerebrovascular Disorders

Interventions

Drug Therapy; Aspirin; Clopidogrel; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Emergency Treatment; Health Records, Personal

Condition Hierarchy (Ancestors)

Stroke; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Brain Infarction; Brain Ischemia; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Intervention Hierarchy (Ancestors)

Therapeutics; Salicylates; Hydroxybenzoates; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Ticlopidine; Thienopyridines; Thiophenes; Sulfur Compounds; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Anticholesteremic Agents; Hypolipidemic Agents; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Enzyme Inhibitors; Lipid Regulating Agents; Therapeutic Uses; Medical Records; Records; Data Collection; Epidemiologic Methods; Investigative Techniques

Study Officials

• Wei Wang, PhD, MD

  Tongji Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Vice President of Tongji Hospital

Study Record Dates

• First Submitted: March 30, 2017
• First Posted: April 20, 2017
• Study Start: March 3, 2018
• Primary Completion: December 31, 2021
• Study Completion: September 1, 2022
• Last Updated: December 7, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)